Hoth Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced interim results from its ongoing Phase 2a clinical study (CLEER-001) of HT-001, a novel topical therapy developed to address skin toxicities induced by epidermal growth factor receptor inhibitors (EGFRIs) in cancer patients. The study, which evaluates the efficacy of HT-001 in treating EGFRI-induced cutaneous toxicities, reported that 100% of enrolled patients achieved at least one primary endpoint of clinical dermatologic improvement. Additionally, over 65% of participants experienced reductions in pain and itching, with no patients requiring dose reductions or discontinuation of their EGFRI therapy. The topical treatment was well tolerated, with no serious adverse events reported. Hoth Therapeutics will present these interim results at a Key Opinion Leader event, featuring insights from specialists in derm-oncology and dermatology, to discuss how HT-001 could potentially redefine supportive care standards for oncology patients.